Novel design for a phase IIa placebo-controlled, double-blind randomized withdrawal study to evaluate the safety and efficacy of CNV1014802 in patients with trigeminal neuralgia

BACKGROUND: Trigeminal neuralgia (TN) is a rare severe unilateral facial pain condition. Current guidelines in trigeminal neuralgia management recommend sodium channel blockers – carbamazepine or oxcarbazepine – as the first-line treatment. However, the currently available drugs are often associated...

Descripción completa

Detalles Bibliográficos
Autores principales: Zakrzewska, Joanna M, Palmer, Joanne, Ettlin, Dominik A, Obermann, Mark, Giblin, Gerard MP, Morisset, Valerie, Tate, Simon, Gunn, Kevin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4222641/
https://www.ncbi.nlm.nih.gov/pubmed/24267010
http://dx.doi.org/10.1186/1745-6215-14-402

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4222641/
https://www.ncbi.nlm.nih.gov/pubmed/24267010
http://dx.doi.org/10.1186/1745-6215-14-402

Ejemplares similares